High specificity for the DNA repair enzyme PARP1 with therapeutic effect. Promising new targeted antitumor drug, which is already in clinical trials. High tumor-background fluorescent ratio. Toxicity profile is known and similar to Olaparib. Here, LIG4 is linked to neoplasm.